NEW YORK, Aug. 25, 2004 (PRIMEZONE) -- Amazon Biotech, Inc. (OTCBB:AMZB) today announced the appointment of Arthur Englard M.D., Ph.D., to its Scientific Advisory Board.
Dr. Englard is an Assistant Clinical Professor of Medicine at Columbia College of Physicians and Surgeons and a specialist in Immunology and HIV medicine. For 20 years he has been heavily involved in the AIDS Center Program at St. Lukes/Roosevelt Hospital Center (New York, NY) - ranging from Fellow and Research Associate to Assistant Director. Additionally, Dr. Englard currently runs a private practice in New York City. He has extensive experience working with HIV/AIDS infected patients and with clinical drug protocol involving AIDS patients.
"I am extremely pleased to welcome Dr. Englard to our Company's Board. His dedication to health and medicine we believe will be beneficial for shaping the future of Amazon Biotech as a global leader in the fight against HIV/AIDS. Dr. Englard's strong life science background will significantly enhance the knowledge base of our Board," commented Dr. Chinnici, CEO of Amazon Biotech. "With his many years of specialized experience in Immunology and HIV medicine, Dr. Englard has a deep and thorough understanding of the fundamentals of our approach for treating the disease."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ 0026 is the Company's first such drug, to be used for the treatment of HIV/AIDS. The Company intends to initiate Phase I/II clinical studies of AMZ 0026 shortly, with an eventual goal of a joint venture with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market. Additional information on Amazon Biotech may be found at www.amazonbiotech.com.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.